期刊
BIOMOLECULES & THERAPEUTICS
卷 22, 期 3, 页码 232-238出版社
KOREAN SOC APPLIED PHARMACOLOGY
DOI: 10.4062/biomolther.2014.030
关键词
Alzheimer's disease; 4-O-methylhonokiol; APP/PS1 double transgenic; Antioxidant; Beta-site APP-cleaving enzyme
资金
- Yeungnam University Research Grant
- National Research Foundation Grant - Korea government (MSIP) (MRC) [2008-0062275]
- National Research Foundation of Korea [2008-0062275] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Alzheimer's disease (AD) is the most common neurodegenerative disease without known ways to cure. A key neuropathologic manifestation of the disease is extracellular deposition of beta-amyloid peptide (A beta). Specific mechanisms underlying the development of the disease have not yet been fully understood. In this study, we investigated effects of 4-O-methylhonokiol on memory dysfunction in APP/PS1 double transgenic mice. 4-O-methylhonokiol (1 mg/kg for 3 month) significantly reduced deficit in learning and memory of the transgenic mice, as determined by the Morris water maze test and step-through passive avoidance test. Our biochemical analysis suggested that 4-O-methylhonokiol ameliorated A beta accumulation in the cortex and hippocampus via reduction in beta-site APP-cleaving enzyme 1 expression. In addition, 4-O-methylhonokiol attenuated lipid peroxidation and elevated glutathione peroxidase activity in the double transgenic mice brains. Thus, suppressive effects of 4-O-methylhonokiol on A beta generation and oxidative stress in the brains of transgenic mice may be responsible for the enhancement in cognitive function. These results suggest that the natural compound has potential to intervene memory deficit and progressive neurodegeneration in AD patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据